Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)

NCT03452579 is registered in ClinicalTrials.gov with David Peereboom as lead sponsor.

NCT NCT03452579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03452579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
Lead sponsor
David Peereboom
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 21, 2018
Completion date
June 30, 2025
Enrollment
90 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma